BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17166910)

  • 1. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules.
    Gallois-Montbrun S; Kramer B; Swanson CM; Byers H; Lynham S; Ward M; Malim MH
    J Virol; 2007 Mar; 81(5):2165-78. PubMed ID: 17166910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    Chiu YL; Witkowska HE; Hall SC; Santiago M; Soros VB; Esnault C; Heidmann T; Greene WC
    Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15588-93. PubMed ID: 17030807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
    Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
    J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins.
    Gallois-Montbrun S; Holmes RK; Swanson CM; Fernández-Ocaña M; Byers HL; Ward MA; Malim MH
    J Virol; 2008 Jun; 82(11):5636-42. PubMed ID: 18367521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
    Wichroski MJ; Robb GB; Rana TM
    PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity.
    Izumi T; Burdick R; Shigemi M; Plisov S; Hu WS; Pathak VK
    J Virol; 2013 Oct; 87(20):11047-62. PubMed ID: 23926332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity.
    McDougall WM; Smith HC
    Biochem Biophys Res Commun; 2011 Sep; 412(4):612-7. PubMed ID: 21856286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical fractionation and purification of high-molecular-mass APOBEC3G complexes.
    Chiu YL
    Methods Mol Biol; 2011; 718():185-206. PubMed ID: 21370050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
    Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
    PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
    Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
    J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
    Pion M; Granelli-Piperno A; Mangeat B; Stalder R; Correa R; Steinman RM; Piguet V
    J Exp Med; 2006 Dec; 203(13):2887-93. PubMed ID: 17145955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members.
    Huang J; Liang Z; Yang B; Tian H; Ma J; Zhang H
    J Biol Chem; 2007 Nov; 282(46):33632-33640. PubMed ID: 17848567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subcellular localization of APOBEC3G by confocal laser scanning microscope (CLSM)].
    Yang YS; Li L; Li ZL; Zeng Y
    Bing Du Xue Bao; 2007 Jan; 23(1):16-21. PubMed ID: 17886715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA.
    Friew YN; Boyko V; Hu WS; Pathak VK
    Retrovirology; 2009 Jun; 6():56. PubMed ID: 19497112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.